Accendra Health, Inc. filings document operating results, material events and capital-structure matters for a NYSE-listed home healthcare company with common stock trading under ACH. Form 8-K reports furnish quarterly and annual financial results and record material agreements, shareholder voting matters and balance-sheet disclosures.
Proxy materials describe governance, executive compensation and related shareholder matters. The filings also identify the company as a Virginia corporation and provide formal disclosure around its continuing operations following the completed sale of its former Products & Healthcare Services business.
Accendra Health, Inc. reported results from its 2026 Annual Meeting of Shareholders. Shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan, which replaces the prior 2023 plan and allows the Board’s Our People & Culture Committee to grant equity and other incentive awards to employees, non-employee directors and consultants.
At the meeting, 76,437,917 shares were entitled to vote and 62,134,133 shares were voted, representing approximately 81.29% participation. Six director nominees each received over 48.7 million votes for, including 51,189,677 votes for Teresa L. Kline, with detailed vote counts and broker non-votes reported for all proposals.
Charles Schwab Investment Management Inc. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 3,635,526 shares of Accendra Health Inc. common stock (CUSIP 690732102), representing 4.75% of the class as of 03/31/2026. The filing shows sole voting and sole dispositive power over the same 3,635,526 shares. The amendment is signed by Omar Aguilar on 05/13/2026.
Accendra Health, Inc. reported a net loss from continuing operations of $6.5 million, or $0.08 per share, for the quarter ended March 31 2026, compared with a loss of $3.8 million a year earlier. Net revenue declined 6.8% to $627.8 million, mainly due to terminated contracts with a major commercial payor that represented $37 million, or 6%, of quarterly revenue and nearly all capitation revenue.
Operating income was $17.1 million, helped by a $52 million gain on sales of patient service equipment linked to the payor exit and lower exit and realignment costs, but higher interest expense of $32.3 million pushed results into a loss. Cash flow from operating activities was an outflow of $50.1 million, while cash and cash equivalents increased to $336.9 million after equipment sale proceeds and additional revolver borrowings.
The company remains highly leveraged, with total debt of $2.10 billion against a balance sheet deficit of $464.8 million. A substantial portion of debt, including Term Loan A and the revolving credit facility, is classified as current due to 2027 maturities. Management has obtained creditor commitments for a “Balance Sheet Optimization Transaction” to refinance Term Loan A into new 9.000% senior secured first lien notes due 2032, amend and extend the revolver to 2030, and exchange the 2029 and 2030 unsecured notes into new secured notes, and believes this will provide sufficient liquidity over the next twelve months.
Accendra Health is pursuing a comprehensive balance sheet overhaul built around new secured debt, note exchanges and amended bank facilities. The company agreed to offer $326.25 million of new 9.000% Senior Secured First Lien Notes due 2032, alongside exchange offers and consent solicitations for its existing 4.500% 2029 and 6.625% 2030 senior notes.
Certain noteholders and term loan lenders have committed, subject to conditions, to backstop $261.0 million of the new first lien notes and up to an additional $65.25 million, and to tender all of their existing notes in the exchanges. Revolving lenders have committed to a new $300.0 million revolving credit facility due 2030, and term lenders have agreed to consents and covenant changes, including waiving mandatory prepayments tied to $400.0 million of asset sale proceeds.
The company’s confidential investor deck highlights its post-divestiture profile as a pure‑play home‑based care platform with about $2.8 billion of FY2025 revenue, diversified chronic‑care exposure, and management’s projections for mid‑teens adjusted EBITDA margins, strong free‑cash‑flow generation and lower leverage after the transaction.
Accendra Health reported a first-quarter 2026 net loss from continuing operations of $6.5 million, or $0.08 per share, on net revenue of $627.8 million, down from $673.9 million a year earlier. Operating income was $17.1 million, but higher interest expense contributed to the loss.
Non-GAAP results weakened, with adjusted net loss of $3.1 million versus adjusted net income of $23.2 million and adjusted EBITDA of $58.4 million versus $96.0 million. Free cash flow turned slightly negative at $(2.0) million. Cash rose to $336.9 million, while net debt remained high at $1.77 billion.
The company also announced commitments from existing creditors for a more than $1.5 billion comprehensive balance sheet optimization transaction intended to extend debt maturities, reduce total leverage and reset its capital structure as it continues its shift to a pure play home-based care business.
Accendra Health, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on six director nominees, auditor ratification, a say-on-pay advisory vote, and approval of an amended 2023 Omnibus Incentive Plan. The record date is March 18, 2026, and the meeting will be held online on May 14, 2026.
The company highlights its strategic shift after selling its Products & Healthcare Services business on December 31, 2025, becoming a more focused, pure-play home-based care provider through its Apria and Byram Healthcare brands. For 2025, Accendra generated total revenue of $10.672 billion, total adjusted operating income of $215 million, adjusted EBITDA of $424 million, and total adjusted net income per share of $0.61, using non-GAAP measures reconciled in Appendix B.
Proxy materials emphasize corporate governance practices such as a majority voting standard for uncontested director elections, proxy access, independent board leadership, and board-level oversight of risk, ESG, and cybersecurity. Executive pay is heavily performance-based, with the CEO’s 2025 target compensation 90% variable, including annual incentives tied to adjusted EBITDA, revenue, and net debt reduction, and long-term incentives split between performance share units and restricted stock units.
Accendra Health, Inc. Schedule 13G: Kevin M. Webb reports beneficial ownership of 4,287,431 shares of Common Stock, representing 5.61% of the class as of 03/12/2026. The filing states Mr. Webb has sole voting power and sole dispositive power over all 4,287,431 shares.
The submission lists the issuer address as 10900 Nuckols Road, Suite 400, Glen Allen, Virginia, and is signed by Kevin M. Webb on 03/30/2026.
Accendra Health Inc amendment to a Schedule 13G/A states that The Vanguard Group reports 0 shares beneficially owned of Accendra Health Inc common stock as of the filing. The amendment notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.
Accendra Health President & CEO Edward A. Pesicka reported a tax-related share disposition, not an open-market stock sale. On the Form 4, 58,945 shares of common stock were surrendered at $2.03 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold to outside investors. After this transaction, Pesicka directly holds 1,090,477 shares of Accendra Health common stock, indicating he retains a substantial equity position in the company.